No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Brain
|
Clear Evidence |
Clear Evidence |
(STOP STUDY) GLIOMA 0/50 2/50 0/50 1/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 3/50 2/50 4/50 22/80
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA OR CARCINOMA 1/50 0/50 0/50 1/50 8/50 4/73, STOP STUDY 3/50 7/50 9/50 10/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 8/50 10/50 7/50 15/50 20/50 9/80
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 6/50 7/50 9/50 20/50 31/50 6/73, STOP STUDY 27/50 23/50 30/50 13/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 6/50 12/50 11/50 7/50 9/50 32/80; HISTIOCYTIC SARCOMA 3/50 2/50 7/50 4/50 7/50 4/80
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 4/50 2/50 4/50 6/50 2/50 51/73, STOP STUDY 8/50 22/50 8/50 33/50; HISTIOCYTIC SARCOMA 0/50 0/50 4/50 5/50 7/50 4/73, STOP STUDY 5/50 2/50 7/50 2/50
|
Neoplastic Lesions
|
Yes
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Intestines (Small)
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/50 1/50 1/50 1/50 2/50 0/73
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/49 0/49 0/48 0/50 2/50 0/80
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/50 3/48 1/49 0/73, STOP STUDY 4/48 1/50 3/49 1/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 15/49 14/49 15/50 19/50 16/50 2/80
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 21/50 23/50 30/50 25/48 33/48 5/72, STOP STUDY 27/49 19/49 19/50 11/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 4/50 15/50 19/50 24/50 25/50 22/78
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 21/50 23/50 19/50 31/49 35/50 3/73, STOP STUDY 36/50 28/50 32/50 17/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOACANTHOMA, ADENOCARCINOMA, OR MALIGNANT MIXED TUMOR 0/50 2/50 4/50 12/50 15/50 16/80
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Ovary
|
Clear Evidence |
Clear Evidence |
BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 1/49 0/49 1/48 9/50 8/50 6/79; ADENOMA OR BENIGN MIXED TUMOR 2/49 4/49 1/48 4/50 6/50 2/79
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/50 0/50 0/50 0/50 5/50 0/73, STOP STUDY 1/50 4/50 4/50 3/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Subcutaneous Tissue
|
Clear Evidence |
Equivocal Evidence |
NEUROFIBROSARCOMA OR SARCOMA 1/50 2/50 3/50 5/50 3/50 3/80
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Vascular System (Heart)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 0/50 0/50 1/49 21/50 23/80
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Vascular System (Heart)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 0/49 1/50 5/48 20/48 4/73, STOP STUDY 15/50 7/50 33/50 13/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Zymbal Gland
|
Clear Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/50 0/50 0/50 0/50 0/50 2/80
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Zymbal Gland
|
Clear Evidence |
Equivocal Evidence |
(STOP STUDY) CARCINOMA 1/50 0/50 2/50 2/50
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/51 1/53 10/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/51 0/53 1/51 5/55 0/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/52 1/50 5/51 3/50
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 3/51 2/50 2/49 OR SQUAMOUS CELL CARCINOMA 0/50 0/51 1/50 2/49 COMBINED 0/50 3/51 3/50 4/49
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/51 0/53 0/51 1/55 5/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/52 6/50 8/51 15/50 OR CARCINOMA 1/52 6/50 5/51 7/50 COMBINED 3/52 12/50 13/51 19/50
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/50 6/51 12/50 18/49 OR CARCINOMA 1/50 1/51 4/50 4/49 COMBINED 4/50 7/51 16/50 22/49
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA 27/51 29/53 40/51 34/55 25/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 0/51 0/53 3/51 4/55 11/59
|
Neoplastic Lesions
|
Yes
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Small)
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 0/51 0/53 0/51 2/53 5/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/51 0/53 1/51 3/55 1/59
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/51 3/50 2/49
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 3/52 3/50 9/51 17/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/52 2/50 6/51 5/50 COMBINED 5/52 5/50 15/51 19/50
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 12/50 4/51 12/50 21/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 3/50 7/51 8/50 11/49 COMBINED 15/50 11/51 16/50 25/49
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/51 0/53 3/51 1/55 4/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/51 1/53 0/51 3/55 3/60 COMBINED 1/51 1/53 3/51 4/55 7/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/52 0/50 1/51 2/50
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 25/50 45/51 46/53 45/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 0/51 4/53 6/51 6/55 5/60 OR ADENOMA 0/51 0/53 1/51 1/55 0/60 COMBINED 0/51 4/53 7/51 7/55 5/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MESOTHELIOMA 0/51 3/53 8/51 9/55 26/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 2/51 4/53 5/52 OR SQUAMOUS CELL CARCINOMA 0/50 1/51 1/53 1/52 COMBINED 2/50 3/51 5/53 6/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/51 4/53 8/51 10/55 12/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 1/51 0/55 2/60 COMBINED 0/51 4/53 9/51 10/55 13/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Pancreas Acinar Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 1/51 2/53 4/51 3/53 3/59
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Seminal Vesicle
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/51 0/53 0/51 0/55 1/59 OR CARCINOMA 0/51 0/53 0/51 0/55 1/59 COMBINED 0/51 0/53 0/51 0/55 2/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/51 0/53 2/51 5/55 11/60 OR KERATOACANTHOMA 3/51 5/53 11/51 16/55 10/60 OR TRICHOEPITHELIOMA 0/51 0/53 0/51 1/55 1/60 OR BASAL CELL ADENOMA 0/51 1/53 0/51 3/55 6/60 OR BASAL CELL CARCINOMA 0/51 0/53 2/51 2/55 0/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 0/51 0/55 1/60 COMBINED 4/51 6/53 14/51 24/55 21/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/52 1/50 4/51 11/50
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
FIBROMA 2/51 8/53 11/51 15/55 7/60 OR FIBROSARCOMA 0/51 1/53 0/51 0/55 1/60 OR SARCOMA 0/51 0/53 2/51 3/55 2/60 COMBINED 2/51 9/53 13/51 16/55 10/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/51 2/53 3/52 OR CARCINOMA 0/50 0/51 0/53 1/52 COMBINED 0/50 0/51 2/53 4/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/51 1/53 2/51 2/55 7/59 OR CARCINOMA 0/51 1/53 4/51 1/55 2/59 COMBINED 0/51 2/53 6/51 3/55 9/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
TRANSITIONAL CELL PAPILLOMA 0/51 0/53 1/51 2/55 1/59 OR TRANSITIONAL CELL CARCINOMA 0/51 0/53 0/51 1/55 1/59 COMBINED 0/51 0/53 1/51 3/55 2/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Vascular System (Unspecified)
|
Clear Evidence |
Equivocal Evidence |
HEMANGIOMA AND HEMANGIOSARCOMA 1/52 2/50 0/51 5/50
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/51 0/53 1/51 3/55 2/60 OR CARCINOMA 2/51 1/53 3/51 2/55 15/60 COMBINED 2/51 1/53 4/51 5/55 15/60
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Adrenal Gland Medulla
|
Clear Evidence |
Equivocal Evidence |
PHEOCHROMOCYTOMA 1/50 3/35 5/64 1/50
|
May Have Been Related
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Male |
Dosed-Water |
Adrenal Gland Medulla
|
Clear Evidence |
Equivocal Evidence |
PHEOCHROMOCYTOMA 16/50 11/35 24/63 19/49 OR MALIGNANT PHEOCHROMOCYTOMA 2/50 0/35 3/63 2/49 COMBINED 17/50 11/35 27/63 21/49
|
May Have Been Related
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 7/48 10/32 10/62 10/50, CARCINOMA 4/48 9/32 19/62 15/50, COMBINED 11/48 17/32 28/62 23/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 12/50 13/35 18/65 5/50
|
May Have Been Related
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
NEOPLASMS 0/50 1/35 0/65 3/50
|
Neoplastic Lesions
|
Yes
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Intestines (Small)
|
Clear Evidence |
Clear Evidence |
NEOPLASMS 0/50 0/35 1/65 2/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/50 0/35 15/64 6/50, CARCINOMA 0/50 0/35 6/64 3/50, COMBINED 0/50 0/35 19/64 8/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 2/50 1/35 10/65 15/50, CARCINOMA 0/50 1/35 6/65 7/50, COMBINED 2/50 2/35 15/65 20/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 2/35 1/65 3/50, ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 2/50 2/35 2/65 3/50
|
May Have Been Related
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 2/35 8/65 4/50, ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 1/50 2/35 9/65 4/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Equivocal Evidence |
ADENOCARCINOMA 0/50 3/35 6/65 3/50
|
May Have Been Related
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/35 1/65 2/50
|
May Have Been Related
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 3/35 6/65 4/50, SQUAMOUS CELL CARCINOMA 0/50 0/35 3/65 2/50, COMBINED 0/50 3/35 9/65 6/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
BASAL CELL ADENOMA 0/50 3/35 5/65 3/50, BASAL CELL CARCINOMA 0/50 1/35 2/65 2/50, COMBINED 0/50 4/35 7/65 5/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
BASAL CELL ADENOMA 1/50 4/35 26/65 30/50, BASAL CELL CARCINOMA 0/50 1/35 5/65 6/50, COMBINED 1/50 5/35 28/65 32/50; KERATOACANTHOMA 1/50 1/35 4/65 7/50; SEBACEOUS GLAND ADENOMA 0/50 1/35 5/65 5/50, SEBACEOUS GLAND CARCINOMA 1/50 0/35 0/65 1/50, COMBINED 1/50 1/35 5/65 6/50; SQUAMOUS CELL PAPILLOMA 1/50 0/35 3/65 2/50, SQUAMOUS CELL CARCINOMA 0/50 2/35 8/65 7/50, COMBINED 1/50 2/35 11/65 9/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/35 2/65 6/50, CARCINOMA 0/50 3/35 17/65 13/50, COMBINED 0/50 3/35 18/65 19/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Male |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/35 1/65 1/50, CARCINOMA 0/50 0/35 7/65 6/50, COMBINED 0/50 0/35 8/65 7/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Brain
|
Clear Evidence |
Equivocal Evidence |
ASTROCYTOMA 0/50 1/35 1/65 2/50
|
May Have Been Related
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/50 5/31 12/64 12/50, CARCINOMA 2/50 6/31 12/64 15/50, COMBINED 7/50 11/31 24/64 27/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 17/50 19/35 28/65 20/50
|
May Have Been Related
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA 7/50 13/35 27/65 15/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/50 0/35 3/65 1/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
NEOPLASMS 0/50 1/35 6/65 8/50
|
Neoplastic Lesions
|
Yes
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Intestines (Small)
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/50 0/35 1/65 3/50
|
Neoplastic Lesions
|
Yes
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Intestines (Small)
|
Clear Evidence |
Clear Evidence |
NEOPLASMS 0/50 1/35 0/65 2/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/50 0/35 2/65 4/50, CARCINOMA 0/50 0/35 0/65 1/50, COMBINED 0/50 0/35 2/65 5/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/50 6/35 8/65 7/50, CARCINOMA 0/50 0/35 1/65 4/50, COMBINED 0/50 6/35 9/65 11/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 3/35 12/65 9/50, SQUAMOUS CELL CARCINOMA 0/50 1/35 8/65 6/50, COMBINED 2/50 4/35 19/65 15/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 9/35 18/65 15/50, SQUAMOUS CELL CARCINOMA 1/50 1/35 6/65 2/50, COMBINED 1/50 10/35 24/65 17/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 6/49 2/35 12/64 8/48, CARCINOMA 2/49 3/35 11/64 1/48, COMBINED 8/49 5/35 23/64 9/48
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 2/35 5/65 5/50, SQUAMOUS CELL CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 0/50 2/35 6/65 5/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
BASAL CELL ADENOMA 2/50 8/35 23/65 26/50, BASAL CELL CARCINOMA 0/50 2/35 4/65 10/50, COMBINED 2/50 9/35 27/65 28/50; SEBACEOUS GLAND ADENOMA 0/50 1/35 7/65 3/50; SQUAMOUS CELL PAPILLOMA 2/50 3/35 5/65 8/50, SQUAMOUS CELL CARCINOMA 0/50 1/35 7/65 13/50, COMBINED 2/50 4/35 11/65 19/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/35 1/65 1/50, ADENOCARCINOMA 1/50 0/35 0/65 3/50, COMBINED 1/50 0/35 1/65 4/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/35 5/65 3/50, CARCINOMA 0/50 4/35 7/65 14/50, COMBINED 0/50 4/35 11/65 17/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/35 2/65 4/50, CARCINOMA 1/50 3/35 8/65 17/50, COMBINED 1/50 5/35 10/65 20/50
|
Neoplastic Lesions
|
No
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Rats |
F344/N |
Male |
Dosed-Feed |
Forestomach
|
Some Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 2/50 1/50; SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 0/50
|
May Have Been Related
|
Yes
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Intestines (Small)
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 1/50 0/50 0/50 3/50
|
May Have Been Related
|
No
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/50 2/50 1/50 1/50 OR CARCINOMA 0/50 1/50 0/50 0/50 COMBINED 0/50 3/50 1/50 1/50
|
May Have Been Related
|
No
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 7/49 12/50 17/49 41/49; CARCINOMA 5/49 5/50 6/49 12/49
|
Neoplastic Lesions
|
No
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 16/50 19/50 17/50 40/50; CARCINOMA 7/50 3/50 8/50 17/50
|
Neoplastic Lesions
|
No
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Rats |
F344/N |
Male |
Dosed-Feed |
Oral Cavity
|
Some Evidence |
Some Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 0/50 5/51; SQUAMOUS CELL CARCINOMA 0/50 0/50 0/50 1/51; BASOSQUAMOUS TUMOR BENIGN 0/50 0/50 0/50 1/51
|
Neoplastic Lesions
|
No
|
TR-015
|
133-06-2 |
Captan |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-015
|
133-06-2 |
Captan |
Rats |
Osborne Mendel |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-015
|
133-06-2 |
Captan |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Intestines (Small)
|
Positive |
Positive |
(POLYPOID CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-015
|
133-06-2 |
Captan |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Intestines (Small)
|
Positive |
Positive |
(POLYPOID CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-540
|
7220-79-3 |
Methylene blue trihydrate |
Mice |
B6C3F1 |
Female |
Gavage |
Hematopoietic System
|
Equivocal Evidence |
Equivocal Evidence |
MALIGNANT LYMPHOMA 6/50 4/50 9/50 12/50
|
May Have Been Related
|
No
|
TR-540
|
7220-79-3 |
Methylene blue trihydrate |
Mice |
B6C3F1 |
Male |
Gavage |
Hematopoietic System
|
Some Evidence |
Equivocal Evidence |
MALIGNANT LYMPHOMA 2/50 2/50 2/50 5/50
|
May Have Been Related
|
Yes
|
TR-540
|
7220-79-3 |
Methylene blue trihydrate |
Mice |
B6C3F1 |
Male |
Gavage |
Intestines (Small)
|
Some Evidence |
Some Evidence |
CARCINOMA 0/50 1/50 2/50 4/50 ADENOMA OR CARCINOMA 1/50 2/50 4/50 6/50
|
Neoplastic Lesions
|
No
|
TR-540
|
7220-79-3 |
Methylene blue trihydrate |
Rats |
F344/N |
Male |
Gavage |
Pancreas Islet Cell
|
Some Evidence |
Some Evidence |
ADENOMA 4/50 9/50 12/50 8/50 ADENOMA OR CARCINOMA 4/50 9/50 14/50 8/50
|
Neoplastic Lesions
|
Yes
|
TR-546
|
7789-12-0 |
Sodium dichromate dihydrate (VI) |
Mice |
B6C3F1/N |
Female |
Dosed-Water |
Intestines (Small)
|
Clear Evidence |
Clear Evidence |
Duodenum: adenoma (0/50, 0/50, 2/50, 13/50, 12/50); carcinoma (0/50, 0/50, 0/50, 1/50, 6/50); Jejunum: adenoma (0/50, 1/50, 0/50, 2/50, 5/50); Duodenum, Jejunum, or Ileum: adenoma (0/50, 1/50, 2/50, 15/50, 16/50), carcinoma (1/50, 0/50, 2/50, 3/50, 7/50), adenoma or carcinoma (1/50, 1/50, 4/50, 17/50, 22/50)
|
Neoplastic Lesions
|
Yes
|
TR-546
|
7789-12-0 |
Sodium dichromate dihydrate (VI) |
Mice |
B6C3F1/N |
Male |
Dosed-Water |
Intestines (Small)
|
Clear Evidence |
Clear Evidence |
Duodenum: adenoma (1/50, 0/50, 1/50, 5/50, 15/50); Duodenum, Jejunum, or Ileum: adenoma (1/50, 1/50, 1/50, 5/50, 17/50), carcinoma (0/50, 2/50, 1/50, 3/50, 5/50), adenoma or carcinoma (1/50, 3/50, 2/50, 7/50, 20/50)
|
Neoplastic Lesions
|
No
|
TR-546
|
7789-12-0 |
Sodium dichromate dihydrate (VI) |
Rats |
F344/N |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
squamous cell carcinoma (0/50, 0/50, 0/50, 2/50, 11/50); squamous cell papilloma or carcinoma (1/50, 1/50, 0/50, 2/50, 11/50)
|
Neoplastic Lesions
|
No
|
TR-546
|
7789-12-0 |
Sodium dichromate dihydrate (VI) |
Rats |
F344/N |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
squamous cell carcinoma (0/50, 1/50, 0/49, 0/50, 6/49); squamous cell papilloma or carcinoma (0/50, 1/50, 0/49, 0/50, 7/49)
|
Neoplastic Lesions
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Rats |
F344/N |
Female |
Inhalation |
All Organs
|
Some Evidence |
Equivocal Evidence |
malignant mesothelioma 0/50 1/50 1/50 0/50
|
May Have Been Related
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Mice |
B6C3F1/N |
Female |
Inhalation |
All Organs
|
Clear Evidence |
Clear Evidence |
hemangioma or hemangiosarcoma 4/50 6/50 6/50 11/50
|
Neoplastic Lesions
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Rats |
F344/N |
Male |
Inhalation |
All Organs
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 1/50 12/50 28/50 23/50
|
Neoplastic Lesions
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Rats |
F344/N |
Female |
Inhalation |
All Organs
|
Some Evidence |
Some Evidence |
mononuclear cell leukemia 10/50 11/50 13/50 25/50
|
Neoplastic Lesions
|
Yes
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Mice |
B6C3F1/N |
Female |
Inhalation |
Intestines (Small)
|
Clear Evidence |
Equivocal Evidence |
(Duodenum, Jejunum, or Ileum): carcinoma 1/50 1/50 1/50 3/50
|
May Have Been Related
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Mice |
B6C3F1/N |
Male |
Inhalation |
Kidney
|
Clear Evidence |
Clear Evidence |
renal tubule adenoma 0/50 5/50 19/50 10/50 renal tubule carcinoma 0/50 7/50 31/50 18/50 renal tubule adenoma or carcinoma 0/50 11/50 37/50 27/50
|
Neoplastic Lesions
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Rats |
F344/N |
Male |
Inhalation |
Kidney
|
Clear Evidence |
Clear Evidence |
renal tubule carcinoma 0/50 2/50 1/49 1/50
|
Neoplastic Lesions
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Mice |
B6C3F1/N |
Male |
Inhalation |
Liver
|
Clear Evidence |
Equivocal Evidence |
hepatocholangiocarcionoma 1/50 2/50 2/50 3/50
|
May Have Been Related
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Mice |
B6C3F1/N |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma 25/50 21/50 36/50 29/50 hepatocellular carcinoma 8/50 14/50 12/50 17/50 hepatocellular adenoma or carcinoma 28/50 30/50 37/50 38/50 hepatocholangiocarcinoma 0/50 1/50 1/50 2/50
|
Neoplastic Lesions
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Mice |
B6C3F1/N |
Female |
Inhalation |
Lung
|
Clear Evidence |
Equivocal Evidence |
alveolar/bronchiolar carcinoma 1/50 2/50 7/50 5/49
|
May Have Been Related
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Rats |
F344/N |
Male |
Inhalation |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
respiratory epithelium, adenoma 0/49 0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Rats |
F344/N |
Female |
Inhalation |
Thyroid Gland C-Cell
|
Some Evidence |
Some Evidence |
adenoma 3/50 4/50 6/48 11/50; carcinoma 0/50 6/50 2/48 2/50 adenoma or carcinoma 3/50 10/50 8/48 13/50
|
Neoplastic Lesions
|